Zevra Therapeutics, Inc. (ZVRA) - Form 8-K Summary
Business Context and Reporting Period
Zevra Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 5, 2026. The filing announces the issuance of a press release detailing financial results and corporate updates for the second quarter ended June 30, 2026. The company is listed on the Nasdaq Global Select Market under the symbol ZVRA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into this report.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the company has released its Q2 2026 results and scheduled a conference call to discuss them.
Guidance, Outlook, and Management Commentary
Management commentary, guidance, outlook, risks, and contingencies are referenced as being included in the press release (Exhibit 99.1) and the subsequent conference call. The filing itself does not contain these details. A conference call and audio webcast were scheduled for August 5, 2026, at 4:30 p.m. ET to discuss the results.
Investor Verification Checklist
- Review the press release (Exhibit 99.1) for specific Q2 2026 financial figures including revenue, net loss, and cash position.
- Listen to the conference call transcript or recording for management's commentary on clinical progress and future guidance.
- Verify the company's cash runway and burn rate as disclosed in the full financial statements.
- Check for any updates on the status of the company's drug development pipeline mentioned in the corporate updates.